The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 892-899

  Hatakeyama, Hiroto ^a   Akita, Hidetaka ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Liposome; Multifunctional envelope type nano device; Small interfering RNA; Tumor

Indexed keywords

1 METHYL 4,4 BIZ(OCTADECA 9,12 DIEN 1 YLOXY)PIPERIDINE; 1,2 DIOLEOYL 3 DIMETHYLAMMONIUM PROPANE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALANYLPROPYLARGINYLPROPYLGLYCINE; ANTIBODY; APTAMER; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINYLGLYCYLARGININE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR; IMMUNOLIPOSOME; LIPID; LIPOPLEX; LIPOSOME; MACROGOL; MATRIX METALLOPROTEINASE; NUCLEIC ACID; PEPTIDE; PHOSPHATIDYLETHANOLAMINE; PLASMID DNA; POLYCATION; POLYETHYLENEIMINE; PROTEOHEPARAN SULFATE; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; TRYPTOPHYLGLUTAMYLALANYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLHISTIDINYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANINE; TRYPTOPHYLGLUTAMYLALANYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLHISTIDINYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLALANYLGLUTAMYLALANYLLEUCYLGLUTAMYLALANYLLEUCYLALANYLALANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELL TRANSPORT; DRUG BINDING; DRUG EFFICACY; DRUG PENETRATION; DRUG UPTAKE; ENCAPSULATION; ENDOSOME; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOSTIMULATION; KAPOSI SARCOMA; LIPOSOMAL GENE DELIVERY SYSTEM; MEMBRANE FUSION; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MULTIFUNCTIONAL ENVELOPE TYPE NANODEVICE; NANODEVICE; NEOPLASM; OVARY CANCER; PH; PROTEIN TARGETING; REVIEW; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

GENE TRANSFER TECHNIQUES; LIPOSOMES; NEOPLASMS; NUCLEIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 84878836924     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00059     Document Type: Review

References (125)

1. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 4, 145-160 (2005).
2. Scherphof GL, Dijkstra J, Spanjer HH, Derksen JTP, Roerdink FH. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann. N. Y. Acad. Sci., 446 (1 Macromolecule), 368-384 (1985).
3. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 268, 235-237 (1990).
4. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta, 1029, 91-97 (1990).
5. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1066, 29-36 (1991).
6. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A., 88, 11460-11464 (1991).
7. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett., 386, 243-246 (1996).
8. Čeh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. Stealth® liposomes: from theory to product. Adv. Drug Deliv. Rev., 24, 165-177 (1997).
9. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46, 6387-6392 (1986).
10. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release, 74, 47-61 (2001).
11. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat. Med., 9, 713-725 (2003).
12. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 54, 3352-3356 (1994).
13. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev., 40, 89-102 (1999).
14. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm., 190, 49-56 (1999).
15. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 7, 771-782 (2008).
16. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 1, 297-315 (2006).
17. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev., 65, 36-48 (2013).
18. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr. Drug Deliv., 8, 235-244 (2011).
19. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther., 13, 464-477 (2006).
20. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer, 11, 59-67 (2011).
21. Kamiya H, Akita H, Harashima H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov. Today, 8, 990-996 (2003).
22. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther., 15, 1131-1138 (2008).
23. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev., 61, 721-731 (2009).
24. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A., 84, 7413-7417 (1987).
25. Leventis R, Silvius JR. Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles. Biochim. Biophys. Acta, 1023, 124-132 (1990).
26. Behr JP, Demeneix B, Loeffler JP, Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc. Natl. Acad. Sci. U.S.A., 86, 6982-6986 (1989).
27. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun., 179, 280-285 (1991).
28. Ruysschaert JM, el Ouahabi A, Willeaume V, Huez G, Fuks R, Vandenbranden M, Di Stefano P. A novel cationic amphiphile for transfection of mammalian cells. Biochem. Biophys. Res. Commun., 203, 1622-1628 (1994).
29. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control. Release, 98, 317-323 (2004).
30. Kogure K, Akita H, Harashima H. Multifunctional envelope-type nano device for non-viral gene delivery: concept and application of programmed packaging. J. Control. Release, 122, 246-251 (2007).
31. Nakamura T, Akita H, Yamada Y, Hatakeyama H, Harashima H. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc. Chem. Res., 45, 1113-1121 (2012).
32. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev., 63, 152-160 (2011).
33. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, Ueno M, Kobayashi H, Kikuchi H, Harashima H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther., 14, 68-77 (2007).
34. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials, 32, 4306-4316 (2011).
35. Sakurai Y, Hatakeyama H, Sato Y, Akita H, Takayama K, Kobayashi S, Futaki S, Harashima H. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials, 32, 5733-5742 (2011).
36. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol., 83, 97-111 (2004).
37. Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC. PEGylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control. Release, 117, 256-266 (2007).
38. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A., 93, 12349-12354 (1996).
39. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J. Biol. Chem., 273, 26164-26170 (1998).
40. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2, 750-763 (2002).
41. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res., 18, 1042-1048 (2001).
42. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm., 346, 143-150 (2008).
43. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm., 281, 25-33 (2004).
44. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Control. Release, 91, 173-181 (2003).
45. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res., 67, 2938-2943 (2007).
46. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-1070 (2010).
47. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432-2443 (1994).
48. Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol., 66, 43-52 (2010).
49. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta, 1233, 134-144 (1995).
50. Lu Y, Wu J, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, Ratnam M, Lee RJ. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol. Pharm., 4, 707-712 (2007).
51. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res., 14, 8161-8168 (2008).
52. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther., 9, 1542-1550 (2002).
53. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug. Chem., 14, 738-747 (2003).
54. Kim SH, Mok H, Jeong JH, Kim SW, Park TG. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem., 17, 241-244 (2006).
55. Guo W, Lee RJ. Efficient gene delivery via non-covalent complexes of folic acid and polyethylenimine. J. Control. Release, 77, 131-138 (2001).
56. Eliaz RE, Nir S, Marty C, Szoka FC Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res., 64, 711-718 (2004).
57. Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia, 6, 343-353 (2004).
58. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm., 3, 579-588 (2006).
59. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther., 16, 942-946 (2008).
60. Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Murthy RS. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J. Control. Release, 150, 2-22 (2011).
61. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer, 74, 1749-1756 (1996).
62. Shmeeda H, Tzemach D, Mak L, Gabizon A. Her2-targeted PEGylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J. Control. Release, 136, 155-160 (2009).
63. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 8, 1172-1181 (2002).
64. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 66, 6732-6740 (2006).
65. Smith B, Lyakhov I, Loomis K, Needle D, Baxa U, Yavlovich A, Capala J, Blumenthal R, Puri A. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)- conjugated thermosensitive liposomes (HER2(+) affisomes). J. Control. Release, 153, 187-194 (2011).
66. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 65, 11631-11638 (2005).
67. Beuttler J, Rothdiener M, Müller D, Frejd FY, Kontermann RE. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug. Chem., 20, 1201-1208 (2009).
68. Kullberg EB, Nestor M, Gedda L. Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing. Pharm. Res., 20, 229-236 (2003).
69. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med., 3, e6 (2006).
70. Schaffert D, Kiss M, Rödl W, Shir A, Levitzki A, Ogris M, Wagner E. Poly(I : C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm. Res., 28, 731-741 (2011).
71. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res., 15, 1973-1980 (2009).
72. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta, 1515, 144-158 (2001).
73. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm., 342, 194-200 (2007).
74. Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol. Pharm. Bull., 30, 972-978 (2007).
75. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol., 15, 517-525 (2004).
76. Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol. Ther., 19, 2201-2212 (2011).
77. Nishikawa K, Asai T, Shigematsu H, Shimizu K, Kato H, Asano Y, Takashima S, Mekada E, Oku N, Minamino T. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. J. Control. Release, 160, 274-280 (2012).
78. Kang H, O'Donoghue MB, Liu H, Tan W. A liposome-based nanostructure for aptamer directed delivery. Chem. Commun. (Camb.), 46, 249-251 (2010).
79. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, Lu Y. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. Engl., 48, 6494-6498 (2009).
80. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U.S.A., 105, 17356-17361 (2008).
81. Mann AP, Bhavane RC, Somasunderam A, Liz Montalvo-Ortiz B, Ghaghada KB, Volk D, Nieves-Alicea R, Suh KS, Ferrari M, Annapragada A, Gorenstein DG, Tanaka T. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget, 2, 298-304 (2011).
82. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377-380 (1998).
83. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 32, e149 (2004).
84. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. U.S.A., 105, 9343-9348 (2008).
85. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat. Med., 16, 909-914 (2010).
86. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release, 153, 141-148 (2011).
87. Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, Dewa T, Nango M, Oku N. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J. Control. Release, 160, 177-181 (2012).
88. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60, 722-727 (2000).
89. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res., 66, 10073-10082 (2006).
90. Moffatt S, Wiehle S, Cristiano RJ. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther., 13, 1512-1523 (2006).
91. Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int. J. Pharm., 396, 143-148 (2010).
92. Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Release, 162, 225-232 (2012).
93. Asai T, Miyazawa S, Maeda N, Hatanaka K, Katanasaka Y, Shimizu K, Shuto S, Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Cancer Sci., 99, 1029-1033 (2008).
94. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int. J. Pharm., 360, 219-224 (2008).
95. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry, 35, 5616-5623 (1996).
96. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther., 8, 1188-1196 (2001).
97. Li W, Huang Z, MacKay JA, Grube S, Szoka FC Jr. Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J. Gene Med., 7, 67-79 (2005).
98. Walker GF, Fella C, Pelisek J, Fahrmeir J, Boeckle S, Ogris M, Wagner E. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther., 11, 418-425 (2005).
99. Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y, Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. ChemBioChem, 6, 718-725 (2005).
100. Shin J, Shum P, Thompson DH. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release, 91, 187-200 (2003).
101. Masson C, Garinot M, Mignet N, Wetzer B, Mailhe P, Scherman D, Bessodes M. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J. Control. Release, 99, 423-434 (2004).
102. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J. Control. Release, 89, 365-374 (2003).
103. Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem., 10, 703-707 (1999).
104. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta, 1515, 144-158 (2001).
105. Zhang JX, Zalipsky S, Mullah N, Pechar M, Allen TM. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol. Res., 49, 185-198 (2004).
106. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J. Control. Release, 111, 333-342 (2006).
107. Harris TJ, von Maltzahn G, Derfus AM, Ruoslahti E, Bhatia SN. Proteolytic actuation of nanoparticle self-assembly. Angew. Chem. Int. Ed. Engl., 45, 3161-3165 (2006).
108. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J. Gene Med., 7, 657-663 (2005).
109. Boeckle S, Fahrmeir J, Roedl W, Ogris M, Wagner E. Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J. Control. Release, 112, 240-248 (2006).
110. Meyer M, Philipp A, Oskuee R, Schmidt C, Wagner E. Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J. Am. Chem. Soc., 130, 3272-3273 (2008).
111. Li W, Nicol F, Szoka FC Jr. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev., 56, 967-985 (2004).
112. Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Biol. Pharm. Bull., 32, 928-932 (2009).
113. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release, 139, 127-132 (2009).
114. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 11, 373-384 (2010).
115. Hatakeyama H, Ito E, Yamamoto M, Akita H, Hayashi Y, Kajimoto K, Kaji N, Baba Y, Harashima H. A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. Mol. Ther., 19, 1487-1498 (2011).
116. Connor J, Yatvin MB, Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc. Natl. Acad. Sci. U.S.A., 81, 1715-1718 (1984).
117. Straubinger RM, Düzgünes N, Papahadjopoulos D. pH-Sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett., 179, 148-154 (1985).
118. Bailey AL, Cullis PR. Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry, 33, 12573-12580 (1994).
119. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, Scherrer P. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta, 1510, 152-166 (2001).
120. Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, MacLachlan I. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol. Ther., 15, 713-720 (2007).
121. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. Confirming the RNAimediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest., 119, 661-673 (2009).
122. Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer, 131, E781-E790 (2012).
123. Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release, 163, 267-276 (2012).
124. Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H. Gene silencing via R NAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol. Ther., (2013), in press.
125. Akita H, Ishiba R, Hatakeyama H, Tanaka H, Sato Y, Tange K, Arai M, Kubo K, Harashima H. A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like materials as a carrier for plasmid DNA. Adv. Healthcare Mater., in press.